• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
  • Our Services
  • Contact Us
  • Newsletter
  • Top Nav Social Icons

Mobile ID World

Mobile ID World

Identification Revolution

  • Mobile ID
    • What Is Mobile ID?
    • Identity Associations
    • Premier Partners
    • FAQ
  • News
  • Solutions
    • Behavioral
    • Facial Recognition
    • Fingerprint Biometrics
    • Iris Biometrics
    • Second Factor
    • Smart Cards
    • Smartphones
    • Vital
    • Voice
    • Wearable Tech
    • Other
  • Applications
    • Access Control
    • Cloud Technology
    • Commerce
    • Enterprise
    • Healthcare
    • Identification
    • Internet of Things
    • Law Enforcement
    • Strong Online Authentication
  • Exclusive
    • Interviews
    • Featured Articles
    • Podcasts
  • Companies
  • Events

BioIntelliSense Provides BioStickers to Track Effectiveness of Cancer Treatments

March 5, 2021

BioIntelliSense’s wearable BioSticker will soon be used to gather data in clinical trials with cancer patients. To that end, the company has formed a strategic partnership with The Leukemia & Lymphoma Society (LLS), which will be using the stickers to monitor the vital signs of the hematological cancer patients in the study.

BioIntelliSense Provides BioStickers to Track Effectiveness of Cancer Treatments

The BioIntelliSense BioSticker is an FDA-approved single-use device that can be worn on the body for a period of up to 30 days. The data collected with the device can be consolidated and analyzed using the company’s Data-as-a-Service platform, which will also be provided to LLS through the new strategic partnership.

LLS will use the data generated with the BioSticker to gauge the effectiveness of different treatments, linking those treatments to a patient’s symptoms to see how well they respond. The BioSticker is able to track a number of different metrics, including body temperature, heart rate, respiration, and body position.

“Our medical grade devices and data services can have a profound impact on oncology care by unlocking unique and actionable clinical intelligence to guide treatment decisions,” said BioIntelliSense CEO James Mault. “We are extremely proud to be partnering with The Leukemia & Lymphoma Society as a global leader in blood cancer research and support services.”

The BioSticker received FDA approval and was cleared for commercial launch in January of 2020, shortly ahead of the international spread of COVID-19. The pandemic generated much more interest in remote patient monitoring solutions that can provide doctors with accurate medical data while minimizing the need for in-person contact.

BioIntelliSense has since supplemented the BioSticker with the release of a 5G BioHub that will automatically consolidate patient data and upload that data to the cloud. The company also updated its Data-as-a-Service platform to better track common symptoms like sneezing and coughing in real time.

Filed Under: Industry News Tagged With: BioIntelliSense, biometric wearables, BioSticker, cancer treatment, healthcare biometrics, heart rate tracking, physiological biometrics, respiration tracking, temperature tracking, The Leukemia & Lymphoma Society, wearable devices

Related News & Articles

FIDO Alliance Ends Year with Another Batch of FIDO Certifications

Experian Brings More Biometrics to its CrossCore Platform

Another IDEX Card Gets China UnionPay Certification

Primary Sidebar

Register For the Next Virtual Identity Summit

Register now!

Tweets

Sponsored Links

facetec logo

FaceTec’s patented, industry-leading 3D Face Authentication software anchors digital identity, creating a chain of trust from user onboarding to ongoing authentication on all modern smart devices and webcams. FaceTec’s 3D FaceMaps™ make trusted, remote identity verification finally possible. As the only technology backed by a persistent spoof bounty program and NIST/iBeta Certified Liveness Detection, FaceTec is the global standard for Liveness and 3D Face Matching with millions of users on six continents in financial services, border security, transportation, blockchain, e-voting, social networks, online dating and more. www.facetec.com

FACEPHI is a global leader in Facial Recognition technology and in Mobile Biometrics technologies. With a strong concentration in the financial sector, FacePhi’s product is rapidly becoming a service used by banks all over the world. Its implementation doesn’t just save money, it is also a way to attract clients and build loyalty, while increasing the security of transactions for both the customer and the business. To learn more about FacePhi, visit https://www.facephi.com/en/

Recent Posts

  • Kenya’s New President Pushes for Digital ID By Year’s End
  • MDL, Digital ID Gain Momentum in State Efforts
  • Brazil-based Selfie Onboarding Startup Reports 250% Sales Jump, Global Expansion
  • ‘All Partners Remain Committed’ to Digital Travel ID Project: Transport Canada
  • North Carolina DMV Seeks Political Support for MDL

Footer

  • About Us
  • Company Directory
  • Advertise With Us
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Archives
  • CCPA: Do not sell my personal info.

Follow Us

Copyright © 2023 MobileIDWorld